Journal ArticleDOI
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers,Andreas Hochhaus,Eric J. Feldman,John M. Goldman,Carole B. Miller,Oliver G. Ottmann,Charles A. Schiffer,Moshe Talpaz,François Guilhot,Michael W. Deininger,Thomas M. Fischer,S. O'Brien,Richard Stone,Carlo Gambacorti-Passerini,Nigel H. Russell,Jose J. Reiffers,Thomas C. Shea,Bernard Chapuis,Steven Coutre,Sante Tura,Enrica Morra,Richard A. Larson,Alan Saven,Christian Peschel,Alois Gratwohl,Franco Mandelli,Monique Ben-Am,Insa Gathmann,Renaud Capdeville,Ronald Paquette,Brian J. Druker +30 more
TLDR
It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.About:
This article is published in Blood.The article was published on 2002-05-15. It has received 1172 citations till now. The article focuses on the topics: Imatinib mesylate & Imatinib.read more
Citations
More filters
Journal ArticleDOI
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker,François Guilhot,Stephen G. O'Brien,Insa Gathmann,Hagop M. Kantarjian,Norbert Gattermann,Michael W. Deininger,Richard T. Silver,John M. Goldman,Richard Stone,Francisco Cervantes,Andreas Hochhaus,Bayard L. Powell,Janice Gabrilove,Philippe Rousselot,Josy Reiffers,Jan J. Cornelissen,Timothy P. Hughes,Hermine Agis,Thea Kolsen Fischer,Gregor Verhoef,John D. Shepherd,Giuseppe Saglio,Alois Gratwohl,Johan Lanng Nielsen,Jerald P. Radich,Bengt Simonsson,Kerry Taylor,Michele Baccarani,Charlene So,Laurie Letvak,Richard A. Larson +31 more
TL;DR: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
Journal ArticleDOI
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Neil P. Shah,John Nicoll,Bhushan Nagar,Mercedes E. Gorre,Ronald Paquette,John Kuriyan,John Kuriyan,Charles L. Sawyers +7 more
TL;DR: Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib are identified.
Journal ArticleDOI
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Ellen Weisberg,Paul W. Manley,Werner Breitenstein,Josef Brüggen,Sandra W. Cowan-Jacob,Arghya Ray,Brian J. P. Huntly,Doriano Fabbro,Gabriele Fendrich,Elizabeth Hall-Meyers,Andrew L. Kung,Andrew L. Kung,Jürgen Mestan,George Q. Daley,Linda Callahan,Laurie Catley,Cara Cavazza,Azam Mohammed,Donna Neuberg,Renee D. Wright,D. Gary Gilliland,James D. Griffin +21 more
TL;DR: AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models, suggests this is a promising new inhibitor for the therapy of CML and Ph+ ALL.
Journal ArticleDOI
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
TL;DR: This work describes how this drug discovery programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.
Journal ArticleDOI
Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients
Stephen T. Sonis,Linda S. Elting,Dorothy M. K. Keefe,Douglas E. Peterson,Mark M. Schubert,Martin Hauer-Jensen,B. Nebiyou Bekele,Judith E. Raber-Durlacher,J. Peter Donnelly,Edward B. Rubenstein +9 more
TL;DR: An international multidisciplinary panel of experts assembled to create clinical practice guidelines for the prevention, evaluation, and treatment of mucositis.
References
More filters
Journal ArticleDOI
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker,Moshe Talpaz,Debra Resta,Bin Peng,Elisabeth Buchdunger,John Ford,Nicholas B. Lydon,Hagop M. Kantarjian,Renaud Capdeville,Sayuri Ohno-Jones,Charles L. Sawyers +10 more
TL;DR: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Journal ArticleDOI
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
TL;DR: An unsuspected abnormality in all cells from the nine patients with chronic myelogenous leukaemia has been detected with quinacrine fluorescence and various Giemsa staining techniques, suggesting that there may be a hitherto undetected translocation between the long arm of 22 and thelong arm of 9, producing the 9q+ chromosome.
Journal ArticleDOI
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Brian J. Druker,Shu Tamura,Elisabeth Buchdunger,Sayuri Ohno,Gerald M. Segal,Shane Fanning,Jürg Zimmermann,Nicholas B. Lydon +7 more
TL;DR: A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein and it was found that this compound may be useful in the treatment of bcr–abl–positive leukemias.
Journal ArticleDOI
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
Nancy L. Harris,Elaine S. Jaffe,Jacques Diebold,G. Flandrin,H. Konrad Muller-Hermelink,James W. Vardiman,T. Andrew Lister,Clara D. Bloomfield +7 more
TL;DR: The experience of developing the WHO Classification has produced a new and exciting degree of cooperation and communication between oncologists and pathologists from around the world, which should facilitate progress in the understanding and treatment of hematologic malignancies.
Journal ArticleDOI
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Mercedes E. Gorre,Mansoor Mohammed,Katharine Ellwood,Nicholas C. Hsu,Ron Paquette,P. Nagesh Rao,Charles L. Sawyers +6 more
TL;DR: It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested.
Related Papers (5)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more